JY
PBLA

Jeff Yass’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Jeff Yass’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed -$12K – 14879
2022
Q2 		$12K Buy
+1
New +$37K ﹤0.01% 12488

Other funds holding PBLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BAMG
Brand Asset Management Group Chesterfield, Missouri $452M AUM 25.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
OFG
Oxford Financial Group Carmel, Indiana $1.97B AUM 22.31% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Jeff Yass's PBLA Position: Q3 2022 in Review

Jeff Yass sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q3 2022, closing a stake of 1 share — an estimated $12K sold.

Jeff Yass first reported a position in PBLA in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 12 funds tracked by Wall St. Rank hold PBLA as of Q3 2022.

  • Jeff Yass reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Jeff Yass sold 1 Panbela Therapeutics, Inc. Common Stock share in Q3 2022, an estimated $12K.
  • Jeff Yass first reported a position in Panbela Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Jeff Yass's Panbela Therapeutics, Inc. Common Stock position peaked at $12K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.